Results from the Anti-CD3 mAb (teplizumab) prevention trial

Tuesday, 17 September 2019, 13:15 - 14:15, Vilanova Hall

Chair: L. Chatenoud, FR

K.C. Herold, US: Clinical data, background, results, features of the participants associated with clinical responses; conclusions and significance

P.S. Linsley, US: Studies of the mechanism of teplizumab

A.G. Ziegler, DE: Commentary